The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
HOME > BUSINESS
BUSINESS
- Asahi Kasei Pharma Poised for a String of Approvals and Launch in 2023
February 14, 2023
- Sawai President Declares Plan to Raise Shipment Prices in FY2023
February 14, 2023
- Zeria to Take over Japan Marketing Authorization for Dafclir from Astellas
February 14, 2023
- AbbVie Rolls Out Skyrizi Auto-Doser in Japan
February 14, 2023
- Adcetris Filed for CTCL Indication in Japan: Takeda
February 14, 2023
- BMS Mulls CAR-T Manufacturing in Japan, Definitive Plans Expected by Year-End
February 14, 2023
- Asahi Kasei to Push Teribone Auto-Injector, but AG Remains an Option: President
February 13, 2023
- Xocova’s Serious Side Effect Cases Total 5: Shionogi
February 13, 2023
- Kyowa Kirin Has No Plans to Launch Biosame of G-Lasta: President
February 10, 2023
- Fuji Pharma/M3’s Dysmenorrhea Drug Hits Main PIII Goal; 2024 Launch Eyed
February 10, 2023
- Spikevax Filed for Kids Aged 6 to 11 in Japan: Moderna
February 10, 2023
- Takeda Wraps Up Acquisition of Nimbus’ TYK2 Immune Therapy
February 10, 2023
- Sumitomo Sees Sales Force as Asset to Lure Collabs; Rep Cut Not in the Cards though Trulicity Deal Ended
February 9, 2023
- Santen’s Glaucoma Med Tapcom Accepted for Review in China
February 9, 2023
- Masao Hirokawa Named Next President of Fujifilm Kyowa Kirin Biologics
February 9, 2023
- Mitsubishi Tanabe Incurs 33 Billion Yen Operating Loss on Medicago Shutdown
February 8, 2023
- Kyowa Kirin’s Crysvita Crosses Blockbuster Line: 2022 Earnings
February 8, 2023
- Takhzyro Adds Pediatric Indication in US: Takeda
February 8, 2023
- Daiichi Sankyo Espha’s Nexium Generic Hits Japan Market
February 8, 2023
- Japan Ethical Drug Sales Surge 5.8% in December: Crecon
February 8, 2023
ページ
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…